Skip to main content
. Author manuscript; available in PMC: 2014 Oct 1.
Published in final edited form as: Mol Cancer Ther. 2013 Jul 26;12(10):2200–2212. doi: 10.1158/1535-7163.MCT-13-0095

Figure 3.

Figure 3

Decreased PTPMeg2 and increased levels of pSTAT3 and Bcl2/Bcl-XL are associated with erlotinib resistance in human lung cancer cells. A, HCC827 cells and acquired erlotinib resistant HCC827/ER cells were treated with increasing concentrations of erlotinib (Erlo) for 48h. Cell growth was analyzed by SRB assay. B, HCC827 and HCC827/ER cells were treated with erlotinib (Erlo, 1 μM) and colony formation assay was performed as described in “Methods”. C, pSTAT3, PTPMeg2, Bcl2, Bcl-XL, etc., were analyzed by Western Blot. D, mRNA levels of Bcl2, Bcl-XL and Mcl-1 were analyzed by RT-PCR.